Can a pharmaceutical manufacturer face liability for failing to bring an allegedly safer drug to market sooner, even when the drug it already sells is not defective?

In Gilead Tenofovir Cases, 20 Cal. 5th 390 (2026) (Gilead), the California Supreme Court answered no under the circumstances presented. The August 2026 decision rejected an attempt to impose liability based on a manufacturer’s drug-development timeline rather than a defect in its marketed product.

The 6–1 ruling has significant implications for more than 20,000 consolidated cases brought by human immunodeficiency virus (HIV) patients. It also draws an important boundary between a manufacturer’s responsibility for the products it sells and its decisions about developing potential alternatives.

The Dispute

In Gilead, plaintiffs brought a negligence claim alleging that Gilead Sciences, Inc. (Gilead) delayed bringing tenofovir alafenamide fumarate (TAF) to market while continuing to sell tenofovir disoproxil fumarate (TDF), both of which are used to treat HIV, exposing them to avoidable kidney, bone, and tooth injuries. The trial court denied Gilead’s motion for summary judgment, and Gilead petitioned for writ of mandate.

The Court of Appeal allowed the negligence claim to proceed, reasoning that alleging a defect is not always necessary in a suit for injuries caused by a manufacturer’s products because plaintiffs could proceed instead under a general negligence theory.

Ultimately, the Supreme Court ruled 6–1 in Gilead’s favor, holding that manufacturers owe no duty to users of a non-defective drug to develop and commercialize an allegedly safer alternative in these circumstances. The decision has significant implications for more than 20,000 consolidated cases brought by HIV patients and limits efforts to impose liability based on drug-development timelines rather than product defects.

Plaintiffs’ Argument

Plaintiffs contended that Gilead knew TAF was as effective as TDF but carried substantially lower risks of serious side effects. They alleged that Gilead stopped developing TAF in 2004, not because of scientific concerns, but to protect TDF sales and maximize profits before patent expiration. Although TAF ultimately received Food and Drug Administration (FDA) approval in 2015, plaintiffs maintained that it could have been available as early as 2006. Importantly, plaintiffs did not argue that TDF was defective or should have been withdrawn from the market. Instead, they relied on California Civil Code section 1714’s general duty of reasonable care, arguing that Gilead unreasonably delayed the additional testing and regulatory steps necessary to commercialize an alternative it already knew was safer. Plaintiffs asserted that they would have switched to TAF and avoided injury had Gilead made it available sooner.

Where Product Safety Meets Development Strategy

Gilead countered that established products liability law requires manufacturers to design, manufacture, and market products free from defects, not to develop alternatives to concededly non-defective drugs.

The company also disputed the premise that it knew TAF was safer when it paused development, emphasizing the preliminary research and the need for further clinical testing. More broadly, Gilead warned that the proposed duty would expose complex scientific and resource-allocation decisions to hindsight-driven litigation, potentially discouraging innovation rather than advancing it.

The trial court denied Gilead’s motion for summary judgment. The Court of Appeal allowed the negligence theory to proceed, reasoning that a product defect is not necessarily required for every negligence claim involving injuries caused by a manufacturer’s product.

The California Supreme Court reversed.

The Court’s Holding: No Duty in These Circumstances

The Supreme Court of California sided with Gilead, holding that manufacturers do not owe users of a non-defective drug a duty to develop and commercialize an allegedly safer alternative in the circumstances presented. Although the court expressed substantial doubt about negligence liability untethered to a product defect, it did not categorically decide whether such liability could ever exist. Instead, applying the foreseeability and public policy factors identified in Rowland v. Christian, 69 Cal.2d 108 (1968), the court recognized an exception to any broader duty of care.

Several considerations drove the analysis:

• Preliminary research is not a reliable verdict on comparative safety. Early clinical studies cannot reliably establish whether an alternative drug will prove safer and equally effective.
• The connection between development decisions and patient injuries is uncertain. It depends on subsequent trial results, FDA approval, and individualized prescribing decisions.
• A new duty could distort research priorities. Requiring manufacturers to pursue alternatives to non-defective drugs could divert resources from unmet medical needs and discourage investigation of backup candidates.

What the Decision Means

For pharmaceutical manufacturers, Gilead is a significant defense victory, but not a blanket exemption from negligence liability.

With this decision, the court limits litigation over development timelines without eliminating traditional avenues of recovery. Manufacturers remain subject to claims involving negligent design, manufacturing defects, inadequate warnings, and other actionable misconduct. For pharmaceutical defendants, this means less exposure to claims based solely on delayed innovation. For plaintiffs, it underscores the importance of identifying a viable product defect or other independently actionable conduct rather than relying only on the delayed availability of an alternative treatment.